首页> 美国卫生研究院文献>other >A New Surgical Technique of Pancreaticoduodenectomy with Splenic Artery Resection for Ductal Adenocarcinoma of the Pancreatic Head and/or Body Invading Splenic Artery: Impact of the Balance between Surgical Radicality and QOL to Avoid Total Pancreatectomy
【2h】

A New Surgical Technique of Pancreaticoduodenectomy with Splenic Artery Resection for Ductal Adenocarcinoma of the Pancreatic Head and/or Body Invading Splenic Artery: Impact of the Balance between Surgical Radicality and QOL to Avoid Total Pancreatectomy

机译:胰十二指肠切除术联合脾动脉切除术治疗胰头和/或身体侵犯脾动脉的导管腺癌的新手术技术:手术根治性和QOL之间的平衡以避免全胰腺切除术

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

For pancreatic ductal adenocarcinoma (PDAC) of the head and/or body invading the splenic artery (SA), we developed a new surgical technique of proximal subtotal pancreatectomy with splenic artery and vein resection, so-called pancreaticoduodenectomy with splenic artery resection (PD-SAR). We retrospectively reviewed a total of 84 patients with curative intent pancreaticoduodenectomy (PD) for PDAC of the head and/or body. These 84 patients were classified into the two groups: conventional PD (n = 66) and PD-SAR (n = 18). Most patients were treated by preoperative chemoradiotherapy (CRT). Postoperative MDCT clearly demonstrated enhancement of the remnant pancreas at 1 and 6 months in all patients examined. Overall survival rates were very similar between PD and PD-SAR (3-year OS: 23.7% versus 23.1%, P = 0.538), despite the fact that the tumor size and the percentages of UICC-T4 determined before treatment were higher in PD-SAR. Total daily insulin dose was significantly higher in PD-SAR than in PD at 1 month, while showing no significant differences between the two groups thereafter. PD-SAR with preoperative CRT seems to be promising surgical strategy for PDAC of head and/or body with invasion of the splenic artery, in regard to the balance between operative radicality and postoperative QOL.
机译:对于侵袭脾动脉(SA)的头部和/或身体的胰导管腺癌(PDAC),我们开发了一种新的近端全切除胰腺切除术,并行脾动脉和静脉切除术,即所谓的胰十二指肠切除术与脾动脉切除术(PD- SAR)。我们回顾性地回顾了总共84例根治性胰十二指肠切除术(PD)患者的头部和/或身体的PDAC。这84例患者分为两组:常规PD(n = 66)和PD-SAR(n = 18)。大多数患者接受术前放化疗(CRT)治疗。术后MDCT清楚地表明,所有接受检查的患者在1和6个月时残余胰腺的增强。 PD和PD-SAR的总生存率非常相似(3年OS:23.7%对23.1%,P = 0.538),尽管PD之前的肿瘤大小和UICC-T4的百分比更高-SAR。 1个月时,PD-SAR的每日总胰岛素剂量显着高于PD-SAR,但此后两组之间无显着差异。考虑到手术根治性和术后QOL之间的平衡,PD-SAR术前CRT似乎是针对脾脏动脉侵犯的头部和/或身体PDAC的手术策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号